• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为肺纤维化诊断标志物的克雷伯斯6(KL-6):一项系统评价与荟萃分析

Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis.

作者信息

Wang Chuanzhu, Wang Qingbao, Liu Tong, Zhu Jun, Zhang Boke

机构信息

Department of Clinical Laboratory, Anhui No. 2 Provincial People's Hospital, Hefei, PR China.

Department of Clinical Laboratory Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, PR China.

出版信息

Clin Biochem. 2023 Apr;114:30-38. doi: 10.1016/j.clinbiochem.2023.01.010. Epub 2023 Jan 24.

DOI:10.1016/j.clinbiochem.2023.01.010
PMID:36706799
Abstract

BACKGROUND

Pulmonary fibrosis (PF) is a respiratory disease with end-stage pathological changes of interstitial lung disease that severely affects the survival of patients. Among the many biomarkers that have been identified, serum Krebs von den Lungen-6 (KL-6) is by far the most frequent marker for detecting pulmonary fibrosis.

METHODS

We searched Medline (Pubmed), Embase, Web of science, and Cochrane databases for articles published between inception and August 2022 in order to explore the association between KL-6 and pulmonary fibrosis. Characteristics of patients and studies included in the articles were extracted by two independent investigators according to the inclusion and exclusion criteria. We reflected the accuracy of KL-6 in distinguishing between PF and non-PF by calculating sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and area under the curve by SROC curves. The presence of heterogeneity was reflected by I in the forest plot, and then the source of heterogeneity was investigated by meta-regression.

RESULTS

We searched for 939 research papers, of which 16 met the inclusion criteria. Meta-analysis showed a sensitivity of 0.87 (95 % CI: 0.78-0.92), specificity of 0.91 (95 % CI: 0.86-0.95), positive likelihood ratio of 10.2 (95 % CI: 6.1, 17.0) and negative likelihood ratio of 0.14 (95 % CI: 0.08, 0.25) for KL-6 in diagnosing pulmonary fibrosis. The area under the receiver operating characteristic curve was 0.95 (95 % CI: 0.93-0.97). The results showed significant heterogeneity in both sensitivity and specificity (I = 94.55 and 91.52, respectively). Meta-regression analysis identified race as the cause of sensitivity heterogeneity and assay methodology as the cause of specificity heterogeneity.

CONCLUSIONS

The analysis of this study suggests that serum KL-6 is a better tool for the diagnosis of pulmonary fibrosis when factors such as disease cause and control group category are not specifically considered.

摘要

背景

肺纤维化(PF)是一种间质性肺疾病终末期病理改变的呼吸系统疾病,严重影响患者生存。在已确定的众多生物标志物中,血清克雷伯斯-冯-登-龙根-6(KL-6)是目前检测肺纤维化最常用的标志物。

方法

我们检索了Medline(Pubmed)、Embase、科学网和考克兰数据库中自数据库建立至2022年8月发表的文章,以探讨KL-6与肺纤维化之间的关联。两名独立研究人员根据纳入和排除标准提取文章中纳入的患者和研究的特征。我们通过计算敏感性、特异性、阳性似然比、阴性似然比以及SROC曲线下面积,来反映KL-6在区分PF和非PF方面的准确性。森林图中的I反映了异质性的存在,然后通过Meta回归研究异质性的来源。

结果

我们检索到939篇研究论文,其中16篇符合纳入标准。Meta分析显示,KL-6诊断肺纤维化的敏感性为0.87(95%CI:0.78-0.92),特异性为0.91(95%CI:0.86-0.95),阳性似然比为10.2(95%CI:6.1,17.0),阴性似然比为0.14(95%CI:0.08,0.25)。受试者工作特征曲线下面积为0.95(95%CI:0.93-0.97)。结果显示敏感性和特异性均存在显著异质性(I分别为94.55和91.52)。Meta回归分析确定种族是敏感性异质性的原因,检测方法是特异性异质性的原因。

结论

本研究分析表明,在未特别考虑疾病病因和对照组类别等因素时,血清KL-6是诊断肺纤维化的较好工具。

相似文献

1
Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis.作为肺纤维化诊断标志物的克雷伯斯6(KL-6):一项系统评价与荟萃分析
Clin Biochem. 2023 Apr;114:30-38. doi: 10.1016/j.clinbiochem.2023.01.010. Epub 2023 Jan 24.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
4
Three-dimensional saline infusion sonography compared to two-dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions.三维盐水灌注超声与二维盐水灌注超声在诊断腔内局灶性病变中的比较。
Cochrane Database Syst Rev. 2017 May 5;5(5):CD011126. doi: 10.1002/14651858.CD011126.pub2.
5
Low-complexity manual nucleic acid amplification tests for pulmonary tuberculosis in children.用于儿童肺结核的低复杂度手动核酸扩增检测
Cochrane Database Syst Rev. 2025 Jun 25;6(6):CD015806. doi: 10.1002/14651858.CD015806.pub2.
6
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.首次就诊时磁共振灌注成像用于鉴别低级别与高级别胶质瘤
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.
7
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.
8
Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people.初级保健医生对有症状人群进行全因痴呆或认知障碍诊断的临床判断。
Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD012558. doi: 10.1002/14651858.CD012558.pub2.
9
Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.经胸多普勒超声心动图用于检测成人肺动脉高压。
Cochrane Database Syst Rev. 2022 May 9;5(5):CD012809. doi: 10.1002/14651858.CD012809.pub2.
10
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

引用本文的文献

1
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease.KL6水平的纵向变化可预测纤维化间质性肺疾病的急性加重。
Sci Rep. 2025 Jul 18;15(1):26061. doi: 10.1038/s41598-025-12236-8.
2
Role of blood Krebs von Lungen-6 in predicting acute exacerbation in patients with idiopathic pulmonary fibrosis.血液中克雷布斯肺-6在预测特发性肺纤维化患者急性加重中的作用。
PLoS One. 2025 May 30;20(5):e0323784. doi: 10.1371/journal.pone.0323784. eCollection 2025.
3
Krebs von den Lungen-6 as a biomarker for distinguishing between interstitial lung disease and interstitial lung abnormalities based on computed tomography findings.
基于计算机断层扫描结果,将肺表面活性物质相关蛋白A6作为区分间质性肺疾病和间质性肺异常的生物标志物。
J Thorac Dis. 2025 Mar 31;17(3):1377-1386. doi: 10.21037/jtd-24-1833. Epub 2025 Mar 26.
4
The significance of periostin in the diagnosis of idiopathic pulmonary fibrosis and prediction of acute exacerbations.骨膜蛋白在特发性肺纤维化诊断及急性加重预测中的意义
J Thorac Dis. 2025 Mar 31;17(3):1364-1376. doi: 10.21037/jtd-24-1882. Epub 2025 Mar 14.
5
Increased circulating levels of SP-D and IL-10 are associated with the development of disease severity and pulmonary fibrosis in patients with COVID-19.SP-D和IL-10循环水平升高与COVID-19患者疾病严重程度及肺纤维化的发展相关。
Front Immunol. 2025 Mar 14;16:1553283. doi: 10.3389/fimmu.2025.1553283. eCollection 2025.
6
Validation of the KL6 Method on the G600II Analyser (Lumipulse) for Clinical Use in Interstitial Lung Disease.用于间质性肺疾病临床应用的KL6方法在G600II分析仪(Lumipulse)上的验证
EJIFCC. 2024 Dec 30;35(4):216-222. eCollection 2024 Dec.
7
Serum KL-6 and the mortality of patients with connective tissue disease-associated interstitial lung disease: A meta-analysis.血清 KL-6 与结缔组织病相关间质性肺疾病患者的死亡率:一项荟萃分析。
Biomol Biomed. 2024 Sep 6;24(5):1105-1116. doi: 10.17305/bb.2024.10368.
8
Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.吡非尼酮不同剂量对特发性肺纤维化患者的疗效:一项前瞻性、观察性、单中心队列研究
Life (Basel). 2023 Oct 26;13(11):2118. doi: 10.3390/life13112118.